Effect of L-arginine versus placebo on intrauterine growth of the fetus in primigravid women

Effect of L-arginine versus placebo on intrauterine growth of the fetus in primigravid women: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N419

Enrollment

150

Registered

2022-03-15

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine growth. Newborn affected by slow intrauterine growth, unspecified

Interventions

Intervention 1: Intervention group: Routine care during pregnancy plus 1000 mg L-arginine capsule (manufactured by Karen Pharmaceutical Co.) daily from 20th week of pregnancy for 12 weeks. Interventio

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age 18 to 40 years; Prime gravid; Singleton pregnancy; Gestational age between 16 to 20 weeks;

Exclusion criteria

Exclusion criteria: Chronic illness such as diabetes or hypertension; Selenium supplementation

Design outcomes

Primary

Measure	Time frame
Internal uterine growth. Timepoint: From the 20th week of pregnancy to the end of pregnancy. Method of measurement: By measuring uterine height and ultrasound monthly.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Darabi

Hamedan University of Medical Sciences

raziehdarbi96@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026